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A B S T R A C T
Background: Bleeding is the major risk of aspirin treatment, especially in the elderly. A consensus de nitionﬁ
clinically signi cant bleeding (CSB) in aspirin primary prevention trials is lacking in the literature.ﬁ
Methods: This paper details the development, modi cation, application, and quality control of a de nitionﬁ ﬁ
clinically signi cant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trial, a primaryﬁ
vention trial of aspirin in 19,114 community-dwelling elderly men and women. In ASPREE a con rmed bleedingﬁ
event needed to meet criteria both for substantiated bleeding and clinical signi cance. Substantiated bleedingﬁ
was de ned as: 1) observed bleeding, 2) a reasonable report of symptoms of bleeding, 3) medical, nursingﬁ
paramedical report, or 4) imaging evidence. Bleeding was de ned as clinically signi cant if it: 1) requiredﬁ ﬁ
transfusion of red blood cells, 2) required admission to the hospital for > 24 h, or prolonged a hospitalization,
with bleeding as the principal reason, 3) required surgery to stop the bleeding, or 4) resulted in death. Bleeding
sites were subclassi ed as upper gastrointestinal, lower gastrointestinal, intracranial (hemorrhagic stroke,ﬁ
subarachnoid hemorrhage, subdural hematoma, extradural hematoma, or other), or other sites. Potential events
were retrieved from medical records, self-report or noti cation from treating doctors. Two reviewers adjudicatedﬁ
each event using electronic adjudication software, and discordant cases were reviewed by a third reviewer.
Adjudication rules evolved to become more strictly de ned as the trial progressed and decision rules were addedﬁ
to assist with frequent scenarios such as post-operative bleeding.
Conclusions: This paper provides a detailed methodologic description of the development of a standardized
de nition for clinically signi cant bleeding and provides a benchmark for development of a consensus de nitionﬁ ﬁ ﬁ
for future aspirin primary prevention trials.
Trial registration: ASPREE is registered on the International Standard Randomized Controlled Trial Number
Register (ISRCTN83772183) and on clinicaltrials.gov (NCT01038583).
1. Background
Aspirin has long been recommended to prevent recurrent events in
patients of all ages with established cardiovascular disease because of
its favorable bene t to risk ratio in this population [ , ]. Evidence isﬁ 1 2
also building for use of aspirin in primary prevention of cardiovascular
disease and cancer, but the balance of risk of bleeding and beneﬁt o f
disease prevention is much more closely matched [ ]. Meta-analyses3 5–
of primary prevention trials and a large cohort studies found a 50 60%–
increased risk for major gastrointestinal or extracranial bleeding with
low-dose aspirin, with age as the strongest risk factor [ ].5 8–
The ASPirin in Reducing Events in the Elderly (ASPREE) trial
primary prevention trial examining the bene ts and risks of dailyﬁ
pirin 100 mg or placebo in 19,114 US and Australian adults aged
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T
years and older (65 years and older for US minorities) [ ]. The primary9
outcome is disability-free survival , with primary endpoints comprising‘ ’
all-cause mortality, incident dementia, or persistent physical disability.
The composite outcome was chosen to allow an overall assessment of
the bene t of aspirin, and di ers from previous primary preventionﬁ ﬀ
trials which generally have focused on cardiovascular outcomes. The
primary safety endpoint is major hemorrhagic events. Hemorrhagic
stroke and non-stroke clinically signi cant bleeding (CSB) are includedﬁ
within this composite outcome. CSB includes non-stroke intracranial
bleeding and extracranial bleeding.
While a consensus de nition for bleeding in cardiovascular trialsﬁ
has been proposed [ ], no similar attempt has occurred for in trials10
aspirin for primary prevention. Previous primary prevention trials have
varied in the sites and severity of bleeding that were reported,
de nition of severe or major bleeding, and whether anemia or a speciﬁ
hemoglobin level was included ( ). During the initial stagesTable 1
developing a de nition of CSB for the ASPREE protocol, operationalﬁ
de nitions from published primary and secondary prevention trials,ﬁ
well as interventional cardiovascular trials, were consulted. These
ﬁnitions were revisited by the co-chairs of the Endpoint Adjudication
Table 1
De nitions of bleeding from aspirin primary prevention trials.ﬁ
Study De nition of Bleeding Dosing of Aspirin Characteristics of studyﬁ
participants
BDS, 1988 [ ]14 • Hemorrhagic stroke (fatal, non-fatal)• Fatal gastric hemorrhage• Fatal peptic ulcer• Non-fatal bleed, not cerebral• Non-fatal peptic ulcer
500 mg/day (or 300mg enteric
coated tablet if later requested)
• Male physicians
PHS I, 1989 [ ]15 • Death from gastrointestinal (GI) hemorrhage• Bleeding events requiring transfusion• Other (easy bruising, hematemesis, melena, nonspeci c gastrointestinal bleeding,ﬁ
epistaxis, or other bleeding)
325mg every other day • Male physicians• 40 84 years old–
ETDRS, 1992 [ ]16 • Hemoglobin < 100 g/L or hematocrit < 0.30• Hematuria• Blood in stool
Reporting method not stated, no indication of severity
325 mg/day • Age 18-70• Diabetes mellitus, with diabetic
retinopathy
HOT, 1998 [ ]17 • Fatal bleeding (GI, cerebral, other)• Non-fatal major bleeding, de ned as life threatening, disabling, or requiringﬁ
hospital admission (GI, cerebral, nasal, other)• Minor bleeding (GI, nasal, purpura, other)
75 mg/day • Age 50-80• Hypertensive• Diastolic BP 100 115 mm–
TPT, 1998 [ ]18 • Hemorrhagic stroke (fatal, non-fatal)• Subarachnoid hemorrhage (fatal, non-fatal)• GI bleeding (Upper, lower, indeterminate)• Other bleeding
Major bleeding: con rmed cerebral hemorrhages and fatal or life-threateningﬁ
hemorrhages at other sites that required transfusion and/or surgery. Intermediate
bleeding episodes: Bleeding not meeting major de nition, eg, macroscopic hematuria,ﬁ
larger bruises, prolonged nose bleeds. Minor bleeding episodes: bruising, nose bleeds,
rectal bleeding, pink or red urine
75 mg/day • Men• Age 45-69• High risk of heart disease
PPP, 2001 [ ]19 • Hemorrhagic stroke• Other intracranial bleeding• “ ”Severe GI bleeding• “ ”Severe ocular bleeding, epistaxis, other bleeding
No de nition of severeﬁ
100 mg/day • Age 50 and older• High cardiovascular risk
WHS, 2005 [ ]20 • Hemorrhagic stroke• GI bleeding (fatal or non-fatal, requiring transfusion)• Peptic ulcer• Hematuria• Easy bruising• Epistaxis
100mg every other day • Women• 45 and older
JPAD, 2008 [ ]21 • Hemorrhagic stroke (fatal, or non-fatal)• GI hemorrhage• Other hemorrhage• Non-bleeding GI event• Anemia
Severe GI hemorrhage de ned as requiring transfusionﬁ
81 or 100 mg/day • Age 30-85• Type 2 diabetes• No history of vascular disease
POPADAD, 2008
[ ]22
GI bleeding no indication of severity 100 mg/day– • Age 40 and older• Type 1 or 2 diabetes• Ankle-brachial index < 0.99• No symptomatic vascular
disease
AAA, 2010 [ ]23 • Hemorrhagic stroke (fatal or non-fatal)• Subarachnoid/subdural hemorrhage (fatal or non-fatal)• GI hemorrhage• Other hemorrhage• Gastrointestinal ulcer• Retinal hemorrhage• Severe anemia (not de ned)ﬁ
Major GI and other hemorrhage de ned as requiring admission to hospital to controlﬁ
bleeding. Admission only to investigate bleeding was not included.
100 mg/day • Age 50-75• No history of vascular disease• Ankle-brachial index < 0.95
JPPP, 2014 [ ]24 • Serious extracranial hemorrhage requiring transfusion or hospitalization• gastrointestinal hemorrhage; gastroduodenal ulcer; re ux esophagitis; erosiveﬂ
gastritis; stomach
100 mg/day • Age 60-85• Cardiovascular risk factors
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Committee in planning how to operationalize the ASPREE CSB endpoint
as de ned in the protocol. They decided that a focus on bleeding thatﬁ
was fatal or required transfusion, hospitalization, or surgery was in
keeping with the trial's overall emphasis on major functional outcomes.
Less serious bleeding episodes or isolated changes in laboratory values
were therefore not included.
As adjudication proceeded, the ASPREE investigators further re nedﬁ
the CSB de nition and aimed to establish adjudication rules that couldﬁ
be applied consistently over time and between di erent adjudicators,ﬀ
and could potentially be adopted for use in future primary prevention
trials. In this paper, we describe the methods for ascertaining possible
bleeding episodes, the development of a standardized de nition of CSB,ﬁ
and methods to achieve consensus through the use of decision rules .“ ”
We use illustrative cases that highlight issues commonly encountered
during adjudication.
2. Methods
2.1. ASPREE study design and participants
The study design and baseline participant characteristics are de-
scribed elsewhere [ , ]. Brie y, ASPREE is a double-blind, rando-9 11 ﬂ
mized trial comparing oral enteric-coated acetyl salicylic acid 100 mg
or matching placebo. Participants age 70 years and older (65 and older
for U.S. minorities) were recruited from Australian general practice and
U.S. community settings. They were free of dementia, physical
ability, cardiovascular disease, and other conditions contraindicating
the use of aspirin or requiring its use. All participants were screened
anemia, and were excluded if their hemoglobin level was < 12 g/dl
men or < 11 g/dl in women. People taking aspirin without a clear
dication were able to participate if they and their physician agreed
discontinue aspirin. ASPREE has multiple Institutional Review Board
approvals in the U.S. and Australia.
Recruitment ended in December 2014 with 16,703 Australian
2411 U.S. participants. The median age of participants at randomiza-
tion was 74 (range 65 98) years and 56% were women. Approximately–
55% of the U.S. cohort were from minority groups. Following enroll-
ment, participants were seen for annual visits and contacted by tele-
phone at the 6-month mark following each visit.
2.2. ASPREE CSB event collection and adjudication process
A structured questionnaire was administered to participants at
month phone calls and annual visits for the purpose of detecting events
that may be primary or secondary endpoints, including CSB events.
With regard to bleeding events, participants were asked In the past“
months, or since we last saw or spoke with you, has your doctor
agnosed or treated you for clinically signi cant bleeding requiringﬁ
hospitalization? A rmative responses were followed by queries about” ﬃ
the name of the hospital and date of admission. Participants and family
Fig. 1. ASPREE Adjudication Process Chart.
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members may have also reported bleeding events at any time by con-
tacting study sta . In addition, medical records from all overnightﬀ
hospitalizations and deaths were screened for possible bleeding events.
Following detection of any potential endpoint, supporting documenta-
tion for events was sought from hospitals, specialists, and general
practitioners or primary care providers ( ).Fig. 1
A case summary was compiled for each event by trained sta at theﬀ
Australian National Coordinating Centre. The rst page of the caseﬁ
summary included a description of the key information points from the
available supporting documents. Case summaries were reviewed by an
experienced medical practitioner and then assigned electronically to
two adjudicators for review who were presented with the case summary
and asked to provide an adjudication outcome. For CSB events, one of
the adjudicators also entered data for event sub-classi cation. Bleedingﬁ
sites were sub-classi ed as upper gastrointestinal, lower gastro-ﬁ
intestinal, intracranial, multiple trauma, or other sites. Intracranial
bleeding was further sub-classi ed as traumatic or non-traumatic.ﬁ
Discordant case were reviewed by a third adjudicator who provided a
ﬁ ﬁnal adjudication outcome and sub-classi cation. CSB adjudicators
were also able to mark di cult cases for discussion on teleconferenceﬃ
calls.
Between 2010 and 2016 intracerebral bleeds were reviewed by the
stroke adjudication committee and intracranial extracerebral bleeds
such as extradural, subdural and subarachnoid hemorrhage, were re-
viewed by the CSB adjudication committee. This process was changed
in late 2016 at the request of the ASPREE Data Safety and Monitoring
Board. Starting in 2017, cases of subarachnoid hemorrhage and cases
where the site of intracranial bleeding was unclear were seen rst byﬁ
the stroke adjudication committee. This change was made to better
align with the extensive neurological expertise on the stroke ad-
judication committee. It also streamlined the adjudication process,
since subarachnoid extension of intracerebral hemorrhage then only
required adjudication by one committee. Events adjudicated to be non-
stroke intracranial bleeds were then sent for further assessment by the
CSB committee. Non-stroke intracranial bleeds were sub-classi ed byﬁ
anatomical location (subdural, extradural, other.)
2.3. Adjudicator web portal
Adjudication of primary and secondary endpoints was facilitated by
the adjudication module of the ASPREE Web Accessible Database. Upon
logging in to the module, adjudicators were only able to access cases
assigned to them and were blinded to the decision of the other
judicator. Following entry of adjudication outcome by the second
judicator, the program detected if the results were discordant, and if
the case automatically appeared on the list of pending adjudications
the third adjudicator.
2.4. Protocol and initial development of clinically signi cant bleedingﬁ
de nitionﬁ
At the commencement of the study, the ASPREE protocol deﬁ
clinically signi cant bleeding as non-stroke intracranial bleedingﬁ
extracranial bleeding that was fatal or required transfusion, hospitali-
zation, or surgery. To test the de nition, the co-chairs of the Endpointﬁ
Adjudication Committee independently adjudicated 67 events between
2011 and 2013 and then discussed discordance and cases that
outside the protocol de nition but were considered to be signi cantﬁ ﬁ
bleeding events. As a result of these discussions transfusion was“ ”
ﬁned as intravascular transfusion of red blood cells; hospitalization‘”
was deﬁned as admission to the hospital for > 24 h, or prolongation
a hospitalization with bleeding as the principal reason; and surgery“
was de ned as any surgical procedure required to stop the bleeding,ﬁ
excluding endoscopic procedures and colonoscopies ( ). FatalTable 2
hemorrhage was de ned as death due to a bleeding event.ﬁ
In addition to meeting the clinically signi cant de nition above,ﬁ ﬁ
ASPREE a con rmed CSB event needs to meet the criteria for subﬁ
stantiated bleeding ( ). Decision rules were developed to supportTable 2
the protocol de nitions as follows: substantiated bleeding wasﬁ “ ”
ﬁned as: 1) observed bleeding, including through endoscopic instru
ments, 2) a reasonable report of symptoms of bleeding (e.g. melena
hematemesis), 3) medical, nursing or paramedical report, or 4) imaging
evidence such as a computed tomography or magnetic resonance
port. Low hemoglobin level, a drop in hemoglobin level, or a positive
fecal occult blood test alone did not satisfy the criterion of substantiated
bleeding.
Following con rmation of the protocol de nition and supportingﬁ ﬁ
decision rules, a committee with expertise in internal medicine,
matology, and gastroenterology was convened. In 2016, a neurologist
consultant was included in the CSB adjudication committee to assist
with di cult cases of intracranial bleeding. Quarterly conference callsﬃ
were held to discuss di cult cases and discordant adjudications,ﬃ
leading to further re nements described below.ﬁ
Table 2
Criteria for substantiation and clinical signi cance of bleeding events in the ASPREE trial, and decision rules. Bleeding events were required to meet both criteriaﬁ
before being recorded as clinically signi cant. Decision rules were applied for relevant cases to ensure consistency over time and between adjudicators.ﬁ
CRITERIA FOR SUBSTANTIATED BLEEDING
A Observed bleeding e.g. bleeding observed at cystoscopy
B Reasonable report of bleeding symptom e.g. description of melena
C Medical, nursing or paramedical report e.g. emergency notes
D Imaging evidence e.g. CT brain showing hemorrhage
CRITERIA FOR CLINICALLY SIGNIFICANT BLEEDING
A Bleeding necessitating red cell transfusion
B Bleeding requiring hospital admission for > 24 h
C Bleeding requiring surgery for hemostasis Excluding endoscopic procedures
D Bleeding resulting in death
DECISION RULES
1 If hospitalisation criterion is to be utilised, bleeding must be the principal reason for hospitalisation, prolongation of hospitalisation or surgery and must be substantiated.
2 A positive fecal occult blood test, anemia, or haemoglobin drop is insu cient to substantiate bleeding.ﬃ
3 Additional adjudication will occur on whether intracranial bleeding was spontaneous (non-traumatic) or induced (traumatic).
4 Elective inpatient surgical procedure (includes therapeutic endoscopic procedures) with prolonged stay, repeat surgery, or transfusion: Does not meet criteria
5 Elective inpatient surgical (includes therapeutic endoscopic procedures) readmitted after discharge primarily for bleeding: Does meet criteria
6 Elective outpatient procedure (includes therapeutic endoscopic procedures) admitted primarily for bleeding: Does meet criteria
7 Non-elective inpatient procedure (includes therapeutic endoscopic procedures) readmitted, prolonged stay, repeat surgery, or transfused: Does meet criteria
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2.5. Development of additional clinically signi cant bleeding decision rulesﬁ
During the trial the CSB committee found it necessary to develop
decision rules related to elective surgery because of the frequency of
elective procedures and peri-operative bleeding in this age group. The
study protocol states that participants will be advised to contact the
research sta or research clinic when any surgery is planned. In gen-ﬀ
eral, cessation of study medication was managed by the treating phy-
sician. If queried about how study medication should be managed prior
to surgery, ASPREE trial sta advised physicians to treat the patient asﬀ
if they were taking aspirin and to tell the patient accordingly whether to
temporarily cease the study medication.
The CSB committee reasoned that bleeding rates should thus be
similar in the aspirin and placebo groups for elective procedures, but
might not be similar for non-elective procedures where study medica-
tion cannot be stopped in advance. Furthermore, because bleeding is
common and expected for many procedures, it was di cult for ad-ﬃ
judicators to determine what constituted excess bleeding above an ex-
pected threshold. To reduce over-reporting of bleeding and mis-
classi cation, bleeding following elective inpatient surgery orﬁ
endoscopic procedures was not counted as CSB, even if the bleeding
was severe, required prolongation of the hospital stay, required trans-
fusion, or required re-operation to stop the bleeding. For patients who
were discharged from the hospital and later readmitted for bleeding, or
were admitted due to bleeding following elective outpatient surgery or
therapeutic endoscopic procedures, the event was adjudicated as a CSB
event. Bleeding following non-elective hospitalized surgery (such as for
hip fractures or emergency coronary bypass surgery) was also classi edﬁ
as a CSB event if it prolonged the hospital stay, or required transfusion,
another operation to stop the bleeding, or re-admission. After several
rounds of case discussion the CSB committee found these rules for post-
surgical bleeding reduced the number of discordant cases and were
generally straightforward to apply.
We describe cases that illustrate how the ASPREE CSB de nitionﬁ
and decision rules were applied.
1) : The participant was admitted to theAnemia without overt bleeding
hospital with iron de ciency anemia, epigastric discomfort, andﬁ
weight loss, and had recently received an iron and blood transfu-
sion as an outpatient. During the admission, upper gastrointestinal
endoscopy showed multiple gastric and duodenal erosions but no
active bleeding. Colonoscopy also did not reveal any bleeding
source. Proton pump inhibitors were prescribed. This case was not
considered to be a CSB event because there was no record of overt
bleeding, and therefore did not meet criteria of substantiated
bleeding. The participant was hospitalized several months later
with hematemesis and that case was adjudicated as a CSB event.
2) : TheBleeding not the principal reason for admission to hospital or death
participant was in a head-on automobile crash and was admitted to
the hospital with facial fractures, pneumocephalus, sternal frac-
ture, bilateral pulmonary contusions, and multiple rib fractures. A
subarachnoid hemorrhage and a subdural hematoma were treated
conservatively. The participant died 24 days later following a
complicated course that included pneumonia. At post-mortem ex-
amination the immediate cause of death was judged to be large
volume aspiration and the underlying cause of death was multiple
injuries sustained in a motor vehicle accident. This case was judged
not to be a CSB event because the intracranial bleeding was not the
principal reason for the hospital admission or the death and the
bleeding was not treated surgically.
3) : TheBleeding not the principal reason for admission to hospital or death
participant had several episodes of hematuria that led to an out-
patient evaluation. A renal ultrasound scan showed multifocal
bladder tumors likely to be transitional cell carcinoma. He was
admitted for elective transurethral resection of the bladder tumor.
Several bladder tumors were resected. Free clot was observed in the
bladder and continuous irrigation was instituted post-operatively.
The patient was discharged after a successful test of void on post-
operative day 2. Although the patient had hematuria and blood
clots were observed in the bladder, the case was adjudicated as
a CSB event because the principal reason for the hospital admission
was to resect the bladder tumors rather than to treat the bleeding.
(Similar cases in women involve hospitalizations for elective
uterine surgery to diagnose or treat suspected malignancy after
outpatient evaluations for vaginal bleeding.)
4) : The participant fellManagement of bleeding as an outpatient
struck his head. A week later an outpatient CT scan showed
subdural hematoma that appeared chronic rather than acute.
participant was advised to return in 4–6 weeks for a repeat scan
sooner if he had more symptoms; the repeat scan showed resolu-
tion. This case was judged not to be a CSB event because the patient
was not admitted or treated surgically.
5) : The particiElective surgical procedures with bleeding complications
pant had an elective lumbar laminectomy and later during
same hospital stay required surgery to drain a lumbar epidural
hematoma. This case was adjudicated as not a CSB event because
the laminectomy was elective, even though the hospital stay
prolonged and surgery was required to treat post-operative
bleeding.
6) : The participantEmergency procedure with documented bleeding
and sustained a hip fracture requiring emergency surgery
transfusion of 2 units of red blood cells for intraoperative bleeding
with a post-operative hemoglobin drop from 11.6 to 6.3 g/dl. This
case was adjudicated as a CSB event as the patient had
traoperative and postoperative blood loss and the procedure
non-elective.
7) : The participantPost-operative bleeding requiring re-admission
derwent elective knee replacement surgery and was discharged,
re-admitted four days later for severe bleeding at the surgical
that required re-operation and drain placement. Although the knee
replacement was elective, this case was adjudicated as a CSB event
since the bleeding required re-admission.
8) Outpatient procedure that required hospital admission for bleeding:
participant had a rectal polyp removed as an outpatient. Following
the procedure there was rectal bleeding with a hemoglobin drop
7.3 g/dl. The participant was admitted to the hospital for
servation and transfusion. Although the polypectomy was elective,
the case was adjudicated as a CSB event since the patient required
admission and transfusion.
9) The participant unexpectedly developedDeath due to bleeding:
throat discomfort, rapidly lost consciousness, and could not
resuscitated. Post-mortem examination showed hemopericardium
and dissection of the thoracic aorta that was judged to be the cause
of death. This case was adjudicated as a CSB event since there
substantiated fatal bleeding.
10) The participant had several sepaNon-stroke intracranial bleeding:
rate events of left hand weakness and paresthesia and an episode
left-sided facial droop and expressive dysphasia. All episodes lasted
only minutes and resolved completely. The participant was
mitted to the hospital where a brain CT scan revealed blood in
central sulcus and thickening of the right pre- and post-central gyri.
An MRI revealed hemorrhage in the central sulcus with superﬁ
ischemia in the pre- and post-central gyri, which were felt to
explained best by amyloid angiopathy. The case was reviewed
the stroke committee and felt not to be a stroke, and was referred
the CSB committee, which adjudicated it as a CSB event.
As the process of re ning the decision rules occurred for much ofﬁ
adjudication period of ASPREE, a decision was taken, with approval
the ASPREE Principal Investigators, to conduct an audit and review
all cases at the end of the ASPREE study. This quality control audit used
the full complement of decision rules to ensure the ASPREE clinically
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signi cant bleeding criteria were applied systematically across all casesﬁ
over the 7 year period of the study. The audit was conducted by two
members of the committee, two independent clinicians and the clinical
Chair of the Endpoint Adjudication Committee. A future publication
will include quantitative information about the number of case reports,
positive and negative con rmation rates, discordance rates, and qualityﬁ
control audit results.
3. Discussion
The purpose of capturing and adjudicating CSB events in ASPREE is
to understand the risk of aspirin treatment for primary prevention in
the elderly, speci cally bleeding events that are important enough toﬁ
require surgery, transfusion or hospitalization, or to result in death. A
de nition of CSB was established that would make clear which clinicalﬁ
categories of bleeding were included and which were not. In most
previous aspirin primary prevention trials to date, the working de ni-ﬁ
tion of clinically signi cant bleeding is not readily available in theﬁ
published literature and often needs to be inferred from tables and
footnotes. Given the absence of clear guidance, the CSB committee
developed decision rules over the course of ASPREE to deal with new
types of bleeding cases as they arose, with features outside the protocol
de nitions, to ensure that similar cases in the future would be ad-ﬁ
judicated systematically in accord with the decision rule. Holding reg-
ular adjudicator teleconferences to discuss di cult and discordantﬃ
cases was an essential tool for developing consensus about bleeding
events that occurred in a wide variety of circumstances and organ
systems.
A consensus bleeding de nition has been proposed to address theﬁ
heterogeneity in bleeding de nitions used in cardiovascular trials inﬁ
acute coronary syndromes and percutaneous coronary interventions
[ ]. This de nition describes ve levels of bleeding from none to fatal,10 ﬁ ﬁ
focuses heavily on procedural bleeding, and incorporates both clinical
events and changes in hemoglobin levels. Other cardiovascular trial
bleeding de nitions include Thrombolysis in Myocardial Infarctionﬁ
(TIMI), International Society on Thromobosis and Hemostasis (ISTH),
and Global Utilization of Streptokinase and Tissue Plasminogen Acti-
vator for Occluded Coronary Arteries (GUSTO) trial criteria [ ]. All12
three of these have subclassi cations of bleeding severity, and the TIMIﬁ
and ISTH major bleeding de nitions include change in hemoglobinﬁ
levels. Similarly, the de nition of major bleeding in the de nitionﬁ ﬁ
proposed for trials of antihemostatic agents (anticoagulants, anti-
platelet drugs, and brinolytic agents) includes a change in hemoglobinﬁ
level [ ]. These trials regularly measure hemoglobin peri-procedu-13
rally, particularly with signi cant interventions. None of these de ni-ﬁ ﬁ
tions was well-suited for a primary prevention trial in which there is no
procedural intervention likely to precipitate bleeding and study he-
moglobin measures are conducted annually.
Previous primary prevention studies have widely variable de ni-ﬁ
tions of what constitutes signi cant bleeding (ﬁ Table 1) [ 14–24]. For
example, the Hypertension Optimal Treatment (HOT) trial reported
major bleeding from gastrointestinal, cerebral and other sites that was
fatal, life-threatening, disabling, or required hospital admission, but did
not include transfusion as an indicator of severity [ ]. In contrast, the17
Aspirin for Asymptomatic Atherosclerosis (AAA) trial included as major
bleeds only those that required hospital admission to control the
bleeding, but not admissions for diagnostic purposes or observation
[ ]. The Japanese Primary Prevention of Atherosclerosis with Aspirin23
in Diabetes (JPAD) reported bleeding from gastrointestinal and other
sites, but did not report the level of severity of bleeding other than to
state that 4 episodes of severe gastrointestinal bleeding required
transfusion in the aspirin group [ ]. Only a few studies reported on21
anemia (not de ned further in AAA or JPAD) or low hemoglobin levelsﬁ
(Early Treatment of Diabetic Retinopathy Study [ETDRS]) [ , , ].16 21 23
This lack of consensus prompted the ASPREE investigators to develop
their own criteria that would represent clinical and patient-important
outcomes related to bleeding. In addition, the di culty of determiningﬃ
from the medical literature clear de nitions of terms or the methodsﬁ
adjudicating bleeding events prompted the development of this report.
There are a number of limitations to the ASPREE de nition of CSB.ﬁ
First, we cannot be certain we have captured all important aspirin-re-
lated bleeding, as some bleeding may result in a subclinical blood
where overt bleeding does not occur and a source is never localized.
However, hemoglobin is measured annually as a safety laboratory
measure in ASPREE; thus di erential changes in hemoglobin andﬀ
development of anemia will be reported separately from CSB. Second,
while our decision rules regarding elective surgical procedures were
developed to improve consistency and concordance of adjudication,
they may have resulted in misclassi cation of some serious bleedingﬁ
events that could have been related to aspirin. Third, we did not include
patients in developing the CSB de nition, and in future work, it willﬁ
important to consider including bleeding events of signi cance toﬁ
tients quality of life that may not have been captured in our criteria.’
Examples of bleeding that patients may consider important are pre-
sentation to the emergency department for epistaxis management
subdural hematomas that are managed in the outpatient setting.
Finally, whether this de nition is broadly generalizable in otherﬁ
pulations and healthcare settings is unknown. The strengths of
approach include independent adjudication of all CSB endpoints by
least two reviewers and ongoing re nement of criteria and decisionﬁ
rules that adjudicators nd easier to apply with consistency.ﬁ
4. Conclusion
This paper presents a detailed description of the development,
adaptation, and application of a de nition of clinically signi cantﬁ ﬁ
bleeding in a large primary prevention trial of aspirin in community-
dwelling elderly men and women. To our knowledge no other trial
presented similarly detailed methods, which are needed given the
portance of bleeding risk in this population. This detailed methodologic
description of the adjudication process and de nition of bleeding eventsﬁ
will aid in the interpretation of the ASPREE trial results. It provides
benchmark for development of a consensus de nition for future aspirinﬁ
primary prevention trials.
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